CL2017001479A1 - Pharmaceutical combination comprising a selective s1p1 receptor agonist - Google Patents

Pharmaceutical combination comprising a selective s1p1 receptor agonist

Info

Publication number
CL2017001479A1
CL2017001479A1 CL2017001479A CL2017001479A CL2017001479A1 CL 2017001479 A1 CL2017001479 A1 CL 2017001479A1 CL 2017001479 A CL2017001479 A CL 2017001479A CL 2017001479 A CL2017001479 A CL 2017001479A CL 2017001479 A1 CL2017001479 A1 CL 2017001479A1
Authority
CL
Chile
Prior art keywords
pharmaceutical combination
selective
receptor agonist
methyl
dioate
Prior art date
Application number
CL2017001479A
Other languages
Spanish (es)
Inventor
Martine Clozel
Luca Piali
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2017001479A1 publication Critical patent/CL2017001479A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

<p>LA PRESENTE INTENCIÓN SE RELACIONA CON UNA COMBINACIÓN FARMACÉUTICA COMPRENDIENDO UN PRIMER INGREDIENTE ACTIVO QUE ES (R)-5-[3- CLORO-4-(2,3-DIHIDROXI-PROPOXI)-BENZ[Z]ILIDEN]-2-([Z]PROPILIMINO)-3-O-TOTIL-TIAZOLIDIN-4-ONA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y UN SEGUNDO INGREDIENTE ACTIVO EL CUAL ES SELECCIONADO DEL GRUPO CONSISTENTE DE METIL FUMARATO, DIMETIL FUMARATO, (N,N-DIETILCARBAMOIL)METIL METIL (2E)BUT-2-EN-1 ,4-DIOATO, Y 2-(2,5-DIOXOPIRROLIDIN-1-IL)ETIL METIL (2E)BUT-2-EN-1 ,4-DIOATO, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.</p><p> THIS INTENTION IS RELATED TO A PHARMACEUTICAL COMBINATION UNDERSTANDING A FIRST ACTIVE INGREDIENT THAT IS (R) -5- [3- CHLORINE-4- (2,3-DIHIDROXI-PROPOXI) -BENZ [Z] ILIDEN] -2 - ([Z] PROPILIMINO) -3-O-TOTIL-TIAZOLIDIN-4-ONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND A SECOND ACTIVE INGREDIENT WHICH IS SELECTED FROM THE GROUP CONSISTING OF METAL FUMARATE, DIMETIL FUMARATE, (N, N- DIETILCARBAMOIL) METHYL METHYL (2E) BUT-2-EN-1, 4-DIOATE, AND 2- (2,5-DIOXOPIRROLIDIN-1-IL) ETHYL METHYL (2E) BUT-2-EN-1, 4-DIOATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME. </p>

CL2017001479A 2014-12-11 2017-06-09 Pharmaceutical combination comprising a selective s1p1 receptor agonist CL2017001479A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2014077469 2014-12-11

Publications (1)

Publication Number Publication Date
CL2017001479A1 true CL2017001479A1 (en) 2018-02-09

Family

ID=54848562

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001479A CL2017001479A1 (en) 2014-12-11 2017-06-09 Pharmaceutical combination comprising a selective s1p1 receptor agonist

Country Status (19)

Country Link
US (5) US10245253B2 (en)
EP (1) EP3229794A1 (en)
JP (3) JP6437119B2 (en)
KR (3) KR20210122315A (en)
CN (1) CN106999462B (en)
AU (1) AU2015359306B2 (en)
BR (1) BR112017012396B1 (en)
CA (1) CA2964616C (en)
CL (1) CL2017001479A1 (en)
EA (2) EA202290017A1 (en)
HK (1) HK1245106A1 (en)
IL (2) IL252701B (en)
MA (2) MA41139A (en)
MX (2) MX2017007651A (en)
PH (1) PH12017501060A1 (en)
SA (1) SA517381489B1 (en)
SG (1) SG11201704569SA (en)
UA (1) UA122063C2 (en)
WO (1) WO2016092042A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2278960T5 (en) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
KR20230147768A (en) 2014-12-11 2023-10-23 액테리온 파마슈티칼 리미티드 Dosing regimen for a selective s1p1 receptor agonist
MA41139A (en) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd PHARMACEUTICAL COMBINATION INCLUDING A SIP1 RECEPTOR SELECTIVE AGONIST
JOP20190207A1 (en) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd Pharmaceutical combination comprising ponesimod
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
KR20230120768A (en) 2022-02-10 2023-08-17 하나 영농조합법인 Seasoned hot sauce and its manufacturing method

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19853487A1 (en) 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
RU2379299C2 (en) 2003-11-21 2010-01-20 Актелион Фармасьютиклз Лтд Derivatives of 5-(benz-(z)-ylidene)thiazolidine-4-one and application thereof as immunosuppressive agents
ES2387192T3 (en) * 2004-10-08 2012-09-17 Forward Pharma A/S Pharmaceutical controlled release compositions comprising a fumaric acid ester
TWI460166B (en) 2006-11-23 2014-11-11 Actelion Pharmaceuticals Ltd New process for the preparation of 2-imino-thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
EP2680010A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
PL2278960T5 (en) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
PL2334378T3 (en) * 2008-08-19 2014-09-30 Xenoport Inc Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
PL2379063T5 (en) 2009-01-09 2022-07-04 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
DE102010048788A1 (en) 2009-02-13 2011-05-19 Amw Gmbh Transdermal system, useful e.g. as monotherapy for indicating e.g. multiple sclerosis, comprises immunomodulator as active agent and active agent-impermeable removable protective coating, adhesive layer and active agent permeable membrane
DE102009008851A1 (en) 2009-02-13 2010-08-19 Amw Gmbh Transdermal system, useful for treating multiple sclerosis and Crohn's disease, comprises an immunomodulator comprising e.g. quinoline, active agent impermeable protective layer, active agent reservoir and a carrier
US20100260755A1 (en) 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
DE112010004626T5 (en) 2009-12-01 2012-10-18 Metanomics Health Gmbh Means and methods for the diagnosis of multiple sclerosis
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
DE102010026879A1 (en) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermal system, useful for indicating and preventing multiple sclerosis, immunomodulator including quinolines or isoxazoles, metabolite forming groups, skin protective layer, a reservoir and a carrier impermeable to active substance
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
AU2012258558A1 (en) 2011-05-26 2013-05-02 Biogen Ma Inc. Methods of treating multiple sclerosis and preserving and/or increasing myelin content
AU2012264688A1 (en) 2011-05-31 2013-11-21 Metanomics Health Gmbh Methods for diagnosing multiple sclerosis
NZ627980A (en) 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US20130314669A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Method and system for assessing visual disorder
JP6324380B2 (en) 2012-07-27 2018-05-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Compounds that are S1P modulators and / or ATX modulators
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
WO2014025709A1 (en) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
US20150220693A1 (en) 2012-08-13 2015-08-06 Biogen Idec Ma Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
ES2795105T3 (en) 2012-08-17 2020-11-20 Actelion Pharmaceuticals Ltd Process for the preparation of (2Z, 5Z) -5- (3-chloro-4 - ((R) -2,3-dihydroxypropoxy) benzylidene) -2- (propylimino) -3- (o-tolyl) thiazolidin-4 -one and intermediate product used in said process
JP2015527372A (en) * 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド Method for administering monomethyl fumarate and prodrug thereof for reducing side effects
CA2882730C (en) * 2012-08-22 2019-12-31 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
KR20210063443A (en) 2012-10-09 2021-06-01 바이오젠 엠에이 인코포레이티드 Combination therapies and uses for treatment of demyelinating disorders
US20150157590A9 (en) * 2012-11-05 2015-06-11 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
US8669281B1 (en) * 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
NZ723459A (en) 2013-03-14 2017-12-22 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
WO2015066515A1 (en) 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
KR20230147768A (en) 2014-12-11 2023-10-23 액테리온 파마슈티칼 리미티드 Dosing regimen for a selective s1p1 receptor agonist
MA41139A (en) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd PHARMACEUTICAL COMBINATION INCLUDING A SIP1 RECEPTOR SELECTIVE AGONIST

Also Published As

Publication number Publication date
MA41139A (en) 2017-10-17
IL252701A0 (en) 2017-08-31
US11672783B2 (en) 2023-06-13
CA2964616C (en) 2020-01-28
JP2017537129A (en) 2017-12-14
MX2021005516A (en) 2022-09-27
MA41481B1 (en) 2022-03-31
MX2017007651A (en) 2017-10-11
CN106999462A (en) 2017-08-01
PH12017501060B1 (en) 2018-03-05
JP6846392B2 (en) 2021-03-24
US11026927B2 (en) 2021-06-08
UA122063C2 (en) 2020-09-10
KR101996245B1 (en) 2019-07-05
MA41481A (en) 2017-12-19
HK1245106A1 (en) 2018-08-24
PH12017501060A1 (en) 2018-03-05
JP6437119B2 (en) 2018-12-12
JP2019011343A (en) 2019-01-24
AU2015359306A1 (en) 2017-07-27
IL252701B (en) 2022-01-01
SA517381489B1 (en) 2022-03-13
US10245253B2 (en) 2019-04-02
CN106999462B (en) 2020-10-23
JP7033642B2 (en) 2022-03-10
EA039629B1 (en) 2022-02-18
SG11201704569SA (en) 2017-07-28
WO2016092042A1 (en) 2016-06-16
JP2021059574A (en) 2021-04-15
EA202290017A1 (en) 2022-03-22
KR20170095302A (en) 2017-08-22
US20240131009A1 (en) 2024-04-25
KR20210122315A (en) 2021-10-08
BR112017012396B1 (en) 2023-12-12
EA201791260A1 (en) 2017-10-31
BR112017012396A2 (en) 2018-04-24
CA2964616A1 (en) 2016-06-16
AU2015359306B2 (en) 2020-07-23
US20190175563A1 (en) 2019-06-13
US20210338640A1 (en) 2021-11-04
IL288907A (en) 2022-02-01
KR20190077131A (en) 2019-07-02
US20240139160A1 (en) 2024-05-02
US20170348287A1 (en) 2017-12-07
EP3229794A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
CL2017001479A1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
NO2022023I1 (en) Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o- tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof
WO2015054500A3 (en) Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
MX2017012848A (en) Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof.
CY1124251T1 (en) CARBOXAMIDE DERIVATIVES
CO2018001383A2 (en) Derivatives of n- [pyridin-4-yl] methyl] -4 - {(1r) -1 - [(3s) -3-methyl-2,5-dioxopyrrolidin-3-yl] ethyl} benzamide as antagonists of the cgrp receptor &#34;
UY36761A (en) SOLID ORAL FORMULATION CONTAINING IRINOTECAN AND METHOD 20 OF PREPARING THE SAME
MX2016014946A (en) Carboxamide derivatives.
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
MX2019012952A (en) Parasiticidal compositions comprising indole derivatives, methods and uses thereof.
MA40781A (en) PHARMACEUTICAL COMPOSITION OF LOW DOSAGE ISOTRETINOIN FOR ORAL USE
EA201890896A1 (en) SOLID PREPARATION FOR ORAL APPLICATION CONTAINING AMORPHOUS SOLIPHENACIN, AND A METHOD FOR ITS OBTAINING
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
FR3005411B1 (en) ASSOCIATION OF ACTIVE INGREDIENTS FOR ORAL ADMINISTRATION TO ENHANCE THE QUALITY OF NAILS.
PH12016502527A1 (en) Stabilized desmopressin
CU20160170A7 (en) CARBOXAMIDE DERIVATIVES
TH172011B (en) Combined pharmaceuticals containing agonists selected to act on S1P1 receptors.
TH172011A (en) Combined pharmaceuticals containing agonists selected to act on S1P1 receptors.
FR3031676B1 (en) COSMETIC COMPOSITION FOR ORAL ADMINISTRATION FOR STRENGTHENING THE SKIN BARRIER.
TH169595A (en) Using the seropitant, an NK-1 Antagonist receptors in itching